In accordance
with 5 CFR 1320, OMB approves this collection for a period of two
years. FDA states that it is developing a method of electronic
collection of this information but that no such method currently
exists. Before resubmitting this ICR for extension, FDA should
implement an electronic form of collection to reduce burden on the
public.
Inventory as of this Action
Requested
Previously Approved
06/30/2013
36 Months From Approved
06/30/2011
1,517
0
1,412
33,146
0
30,421
0
0
0
This clearance submission is a
consolidation of information collection activities associated with
approval of new animal drugs. To gain approval to market an animal
drug, the applicant must file a New Animal Drug Application
containing data to support the safety and effectiveness of the
drug, appropriate labeling, product manufacturing information, and
where applicable, methods to determine residues of the drug in
edible tissue from food producing animals; file a petition to
obtain a waiver from labeling requirements for certain drugs
intended for use in animal feed or drinking water.
Johnny Vilela 301 796-3792
juanmanuel.vilela@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.